When Will Retatrutide Be Available? FDA Status & Release Date

Retatrutide is not yet FDA approved — it's currently in Phase 3 clinical trials (the TRIUMPH program), and the most realistic window for commercial availability in the US is late 2027 to early 2028.

What Is Retatrutide and Why Is Everyone Waiting?

If you want the full breakdown of the drug itself, check out our guide on what retatrutide is and how it works. The short version: retatrutide (LY3437943) is Eli Lilly's triple-hormone agonist — it activates GIP, GLP-1, and glucagon receptors simultaneously. That's one more receptor target than tirzepatide (Mounjaro/Zepbound), and Phase 2 trials showed it can deliver nearly 25% body weight loss at 48 weeks.

For context, that number beats semaglutide and tirzepatide in head-to-head trial comparisons. The buzz is justified. The impatience is justified. But the timeline is what it is.

Current FDA Status: Phase 3 TRIUMPH Trials

As of early 2026, retatrutide is running through the TRIUMPH clinical trial program — Eli Lilly's Phase 3 package. This is the final stage before an FDA submission. Phase 3 trials enroll thousands of patients, typically run 52–72 weeks, and generate the safety and efficacy data regulators need before approving a new drug.

The TRIUMPH trials include studies across multiple populations:

• Adults with obesity (BMI ≥30) or overweight with weight-related comorbidities
• Adults with type 2 diabetes
• Cardiovascular risk populations (MACE outcomes)
• Long-term safety extension cohorts

These trials are actively recruiting at hundreds of US sites. You can check current enrollment status at ClinicalTrials.gov by searching "retatrutide."

What this means practically: retatrutide exists, it works, and Eli Lilly knows it works. They're not running Phase 3 to discover whether it works — they're running it to generate the regulatory evidence package the FDA requires.

Eli Lilly's Timeline: What We Know

Eli Lilly has been measured about timelines publicly, but here's what the evidence points to:

One important caveat: Eli Lilly will almost certainly seek priority review designation from the FDA. This is granted when a drug shows "substantial improvement" over existing treatments. Given that retatrutide's Phase 2 efficacy data outperformed everything currently on the market, priority review is a reasonable expectation — which would compress the review timeline to six months rather than twelve.

Even with priority review, you're realistically looking at 2027 for FDA approval and 2028 for widespread pharmacy availability.

What Is "Retatrutide Discontinuation"? Clearing Up the Confusion

This one trips people up regularly. If you've searched "retatrutide discontinuation" or seen headlines about it being stopped, here's what actually happened:

During the TRIUMPH Phase 3 program, Eli Lilly temporarily paused enrollment in one or more trial arms — not the trials themselves. This is standard in large pharmaceutical trials. Pauses happen for several reasons: data safety monitoring board reviews, protocol amendments, dosing adjustments based on interim data, or manufacturing scale-up issues.

A pause in enrollment ≠ discontinuation of the drug or the program.

Retatrutide has not been discontinued. Eli Lilly is actively investing billions in this drug class. They have every incentive to push retatrutide through to approval — it represents their next major GLP-1 franchise after tirzepatide. The confusion likely originated from a misinterpretation of a trial status update on ClinicalTrials.gov (where "suspended" enrollment gets conflated with cancellation) or misread press releases.

If the program were genuinely discontinued, Eli Lilly would have issued a formal press release and the FDA would have received formal notification. Neither has happened.

Is Retatrutide Available in the USA Right Now?

Not through standard medical channels. You cannot walk into a pharmacy and fill a retatrutide prescription today — the drug isn't approved, and no pharmacy has a commercial supply.

What is available in the US:

1. Clinical trial enrollment If you qualify (based on BMI, diabetes status, cardiovascular risk, and other criteria), you can enroll in a TRIUMPH trial. You'd receive pharmaceutical-grade retatrutide at no cost, with full medical supervision. The tradeoff: you may receive placebo instead of active drug, and trials have strict eligibility criteria.

2. Compounded retatrutide This is the main access route most people are using right now. Compounding pharmacies can legally prepare retatrutide as a non-commercially-available medication. With a valid prescription from a licensed provider, you can access compounded retatrutide monthly. Quality varies by pharmacy, and it requires a willing provider — telehealth platforms have made this significantly easier to access.

If you're looking to source compounded retatrutide, this guide covers where to buy it and what to look for.

How to Access Compounded Retatrutide While You Wait

Compounding is the practical bridge between "not FDA approved" and "I want this now." Here's how it works:

1. Find a licensed provider — a physician, NP, or PA who's familiar with GLP-1 medications and willing to prescribe off-label compounded retatrutide. Telehealth platforms have made this more accessible.

2. Get a prescription — once a provider signs off, the prescription goes to a compounding pharmacy rather than a retail chain.

3. Source from a reputable supplier — the grey zone matters here. Quality control in compounding ranges from excellent (PCAB-accredited pharmacies with third-party testing) to concerning. Do your homework.

For a vetted supplier with transparent quality standards, Ascension Peptides is one of the most established names in the space — they offer retatrutide with documented sourcing and consistent availability.

Pricing for compounded retatrutide currently runs roughly $200–$500/month depending on dose, supplier, and whether insurance covers any portion.

Retatrutide vs. What's Available Now

While you're waiting, it's worth knowing how retatrutide stacks up against what you can already get prescribed. The comparison that matters most is retatrutide vs. semaglutide — since semaglutide (Ozempic/Wegovy) is the current gold standard.

Quick comparison:

If you're debating whether to start semaglutide or tirzepatide while waiting for retatrutide, that's a real question worth discussing with a provider. Both are effective, both are proven. Retatrutide's edge is in the magnitude of weight loss — but "more effective" doesn't help if it's two years away.

What Happens After FDA Approval?

FDA approval doesn't mean same-day pharmacy availability. Here's the post-approval sequence:

1. Manufacturing ramp-up — Lilly needs to produce enough drug to meet US demand, which will be massive. Tirzepatide faced serious supply shortages at launch. Expect similar issues.

2. Price negotiation and insurance coverage — the drug will launch at a high list price (probably $1,000+/month, consistent with other GLP-1s). Insurance coverage will be inconsistent at first, particularly for obesity indications.

3. Pharmacy stocking and distribution — retail chains and specialty pharmacies need to establish supply chains.

4. International rollout — EMA (Europe) and Health Canada typically follow FDA approval within 6–18 months. Other markets come later.

The practical reality: even after FDA approval, expect 6–12 months before you can easily fill a retatrutide prescription at your local pharmacy.

Will Retatrutide Be Approved for Both Obesity and Diabetes?

Almost certainly both, but likely in sequence. Eli Lilly will pursue the indication with the strongest trial data first — and given retatrutide's glucose-lowering profile, a type 2 diabetes indication may come alongside or slightly before the obesity indication.

This matters for insurance coverage. Diabetes medications are covered more consistently than weight-loss drugs. If your provider can prescribe retatrutide for glycemic management (assuming you qualify), you may have better coverage options than someone seeking it purely for weight loss.

The Bottom Line on Timing

If you want the honest version: FDA approval in late 2027 is possible but optimistic. Early 2028 is more realistic. Pharmacy availability following approval adds another 3–6 months for supply to stabilize.

The wait is real. But you're not without options in the meantime. Compounded retatrutide gives you access to the same molecule right now — with the tradeoffs of variable quality control and the need for a prescribing provider.

The question is whether it makes sense to wait, start with an available GLP-1 now, or access compounded retatrutide through legitimate channels while the FDA process plays out.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Retatrutide is not FDA approved. Compounded medications carry risks including variable quality and dosing accuracy. Consult a licensed healthcare provider before starting any new medication or hormone therapy. The author and middlewaynutrition.com are not responsible for decisions made based on this content.